Treats Hep-B

MOA: Incorporates 3TC-triPO4 into DNA chains, resulting in chain termination

Not DOC in HBeAg-negative patients

Need dose adjustment when CrCl < 50

ADE: Well tolerated. Mild increase in ALT

Treats Hep-B

MOA: Inhibits reverse transcriptase and DNA poly through chain termination

HBeAg positive and negative patients see a benefit

Requires dose adjustment when CrCl < 50

ADE: Nephrotoxicity

Treats Hep-B

 MOA: Inhibits HBV replication at priming of DNA poly, reverse tx, synthesis of positive strand

HBeAg positive and negative patients see benefits

ADE: Can cause lamivudine resistance

Treats Hep-B

Adjust dose when CrCl < 50

ADE: High rate of resistance and cross-resistance to lamivudine. Myopathy and peripheral neuropathy.

Treats Hep-B and HIV

HBeAg positive and negative patients see benefits

Adjust dose when CrCl < 50

ADE: Fanconi syndrome, renal insufficiency, osteomalacia, decrease in bone density

PegINF + RBV therapy for 24 weeks

RBV: 800mg po qd

PegINF: 

2a: 180 micrograms SC weekly

2b: 1.5micrograms/kg SC weekly

Week 1-4: PegINF/RBV

Week 4-28: PegINF/RBV + Boceprevir 800mg q8h

If RVR is NOT achieved:

Week 4-36: PegINF/RBV + Boceprevir 800mg q8h

Week 36-48: PegINF/RBV

Week 1-12: PegINF/RBV + Telaprevir 750mg q8h

Week 12-24: PegINF/RBV

If RVR is NOT achieved:

Week 24-48: PegINF/RBV

Treats genotype 1 Hep-C

MOA: Inhibit NS3/4A protease and enhance host's defenses against the virus

Dosing: Take q7-9h with a light meal/snack

Refrigerate until dispensed

ADE: Anemia, neutropenia, vomiting, dysgeusia

Treats genotype 1 Hep-C

MOA: Inhibit NS3/4A protease and enhance host's defenses against the virus

Dosing: q7-9h with about 20g of fat in a meal

ADE: Rash, anemia, pruritis, anorectal burning, N/D

PegINF alfa-2a:

PegINF: 180 mcg/week

RBV (qd): 1000mg if <  75kg, 1200mg if >75mg

PegINF alfa-2b:

PegINF: 1.5mcg/kg/week

RBV (qd):

<65kg: 800mg

65-85kg: 1000mg

85-105kg: 1200mg

>105kg: 1400mg